PRMT5 Inhibitor Salt Forms for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PRMT5, a protein arginine methyltransferase, is aberrantly expressed in various cancers and hemoglobinopathies, contributing to disease progression and providing a therapeutic target, but current inhibitors are limited.
Innovation Solution
Development of pharmaceutically acceptable salts, including hydrochloride, phosphate, and tartrate salts of a compound of Formula I, along with their crystalline forms, to inhibit PRMT5 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors are developed to treat cancers and hemoglobinopathies, then therapeutic effectiveness is improved, but selectivity and off-target effects become critical challenges
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular regions or characteristics of PRMT5. The compounds are structurally optimized to interact with specific residues or pockets in the PRMT5 active site, ensuring selective inhibition of PRMT5 while sparing other PRMT family members and unrelated enzymes. This localized targeting approach improves therapeutic effectiveness while minimizing off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying key molecular parameters of the inhibitor compounds, including substituent groups, stereochemistry, and physicochemical properties. These parameter optimizations are designed to enhance binding affinity for PRMT5 specifically, while maintaining selectivity against off-target enzymes. The structure-activity relationship studies guide these parameter changes to achieve the desired balance between effectiveness and selectivity.
2Reliability
If current PRMT5 inhibitors are used, then some therapeutic benefit is achieved, but limitations in selectivity and availability remain
Solution Approach 1:
The patent applies universality by developing a versatile platform of PRMT5 inhibitors that can address multiple disease indications, including various cancer types and hemoglobinopathies. The compounds are designed with pharmacological properties that enable broad applicability across different pathological conditions involving PRMT5 dysregulation. This multi-functional approach expands inhibitor availability and therapeutic utility beyond single-indication treatments.
Solution Approach 2:
The patent employs segmentation by dividing the PRMT5 inhibitor development into distinct series and compounds (Formula I, Formula II, and specific examples) with varying structural features and selectivity profiles. This segmentation allows for tailored selection of inhibitors based on specific therapeutic needs, disease models, and desired pharmacological properties, thereby enhancing overall availability and adaptability across different application scenarios.
Data Source
AI summary
The disclosure is directed to pharmaceutically acceptable salts of the compound of Formula I (I). Pharmaceutical compositions comprising pharmaceutically acceptable salts of the compound of Formula I, as well as methods of their use and preparation, are also described.